Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01769378 · ClinicalTrials.gov registry record · Phase 3
Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
NCT01769378 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 300 participants.
The verdict
NCT01769378, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of once-weekly dulaglutide compared to placebo in participants with type 2 diabetes who have inadequate glycemic control with sulfonylurea monotherapy.
Interventions
- DRUG Placebo
- DRUG Dulaglutide
- DRUG Glimepiride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2013-01 |
| Est. Completion | 2014-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01769378
The ClinicalTrials.gov registry entry for NCT01769378 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01769378 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01769378 about?
NCT01769378 is a clinical study titled "Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)". The purpose of this study is to assess the efficacy and safety of once-weekly dulaglutide compared to placebo in participants with type 2 diabetes who have inadequate glycemic control with sulfonylurea monotherapy.
What is the current status of trial NCT01769378?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2013-01. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01769378?
The interventions under investigation include: Placebo (DRUG), Dulaglutide (DRUG), Glimepiride (DRUG).
Who is sponsoring clinical trial NCT01769378?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.